News | August 08, 2007

Abiomed Grows 8 Percent for First Fiscal Quarter 2008

Aug. 9, 2007 - Abiomed Inc. today announced financial results for its first quarter of fiscal 2008 with record revenue of $14.1 million, representing growth of 8 percent over a strong first quarter of fiscal 2007, which was up 55 percent over the first quarter of fiscal 2006.

Recent financial and operating highlights include:

- Record revenue of $14.1 million, which represents the highest quarterly revenue in Company history.

- Record total Impella revenue, up 157 percent and record Impella Console revenue.

- Record number of AB5000 Ventricles shipped in a quarter and sixth consecutive record quarter for the number of patients supported on the AB5000.

- Record number of total ventricular assist device (VAD) units shipped of 629. Impella disposables revenue grew 117 percent, AB5000 disposables revenue increased 23 percent, and BVS(R) 5000 disposables revenue declined 26 percent.

- Impella Console revenue increased 400 percent and AB5000 Console revenue decreased 30 percent. The Company expects FDA supplement approval on its iPulse Combination Console in its fiscal third quarter of 2008, which ends December 31, 2007.

- Abiomed has provided a formal written response to questions from the FDA on the Company's 510(k) submission for the Impella 2.5 and has provided the FDA with a report on its recently completed 20-patient U.S. pilot study. Abiomed has also submitted the formal request to initiate a randomized pivotal study for the Impella 2.5.

- Gross margin for the first quarter of fiscal 2008 was 75 percent, up 200 basis points.

- The first quarter of fiscal 2008 GAAP net loss was $8.3 million, or $.26 per share, which included stock option and other stock-based compensation expense of $1.7 million, or $.05 per share and $1.2 million of expense, or $.04 per share, related to an arbitration decision. The net loss for the first quarter of fiscal 2007 was $6.1 million, or $.23 per share and included stock option and other stock-based compensation expense of $1.7 million, or $.06 per share.

"We are pleased with the record revenue achieved this quarter through continued progress broadening our product portfolio and expanding our global reach," said Michael R. Minogue, chairman, CEO and president of Abiomed. "Abiomed is poised for growth with multiple global regulatory milestones pending this fiscal year on the Impella 2.5, Impella 5.0, supplements on the iPulse and AbioCor, and new product submissions."

For more information: www.investor.abiomed.com

Related Content

Sponsored Content | Videos | Cardiovascular Ultrasound| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Italian Boy Becomes Youngest Patient Bridged to Transplant With SynCardia Total Artificial Heart

Andrei, 12, is the world’s youngest patient to be bridged to transplant with the SynCardia Total Artificial Heart. He is pictured after his heart transplant with his surgeon, Antonio Amodeo, M.D., at Bambino Gesù Children’s Hospital in Rome, Italy. Photo courtesy of Business Wire.

News | Congenital Heart| June 22, 2017
A 12-year-old boy at Bambino Gesù Children’s Hospital in Rome, Italy, has become the world’s youngest patient to be...
Abiomed Impella CP pVAD, third-generation CP
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — Abiomed Inc.
tandemLife Tandemheart priming tray cleared by FDA
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — TandemLife began its commercial launch of the TandemLife Priming Tray, a new product designed to simp
Sponsored Content | Videos | Cardiovascular Ultrasound| May 26, 2017
This video, provided in partnership with the American Society of Echocardiography (ASE), is titled "Intraoperative Tr
Impella CP study to investigate door to left ventricular unloading time
News | May 09, 2017
May 9, 2017 — The first patient has been enrolled in the U.S.
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
the Impella pVAD improves survival, mortality in AMI heart attack with cardiogenic shock

Early use of the Impella percutaneous ventricular assist device prior to angioplasty may significantly improve survival for patients in cardiogenic shock.

Feature | Hemodynamic Support Devices| April 28, 2017 | Dave Fornell
Recent clinical study data presented at the American College of Cardiology (ACC) 2017 meeting show new treatment prot
Sponsored Content | Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Overlay Init